Sage Journals: Discover world-class research

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a malignancy with relatively high incidence and poor prognosis. RNA-binding proteins (RBPs) were reported to be dysregulated in multiple cancers and were closely associated with tumor initiation and progression. However, an integrated analysis of the roles of RBPs in HNSCC has not been conducted. In the present study, we obtained transcriptome data and corresponding clinical information of HNSCC patients from The Cancer Genome Atlas database and screened out differentially expressed RBPs between tumor and normal tissues. Subsequently, we utilized a series of bioinformatics analyses to elucidate the potential functions and prognostic value of these RBPs in HNSCC. As a result, a total of 88 aberrantly expressed RBPs were identified, including 63 downregulated and 25 upregulated RBPs. Functional enrichment analysis suggested that the differentially expressed RBPs mainly participated in mRNA metabolic processes, RNA processing, RNA transport, regulation of RNA stability, RNA degradation, and mRNA surveillance pathway. Three RBP genes (NOVA1, EZH2, and RBM24) were determined as prognosis-related hub genes from which EZH2 and NOVA1 were selected to construct a prognostic signature based on LASSO Cox regression algorithm. Further analysis demonstrated that the high-risk patient group stratified by the risk signature has advanced tumor grade and poorer overall survival when compared with low-risk group. Moreover, univariate analysis showed that the risk score, tumor stage, T stage, and N stage were significantly associated with patient overall survival and the multivariate analysis results indicated that the risk score and age were greatly correlated with patient prognosis. Overall, this study provided a comprehensive landscape of RBPs in HNSCC and identified an effective gene signature for predicting the clinical outcomes of HNSCC patient, which may contribute to clinical decision making and individualized cancer treatment.

Get full access to this article

View all access options for this article.

References

Abdel-Wahab

, and Gebauer

(2018). Editorial overview: cancer genomics: RNA metabolism and translation in cancer pathogenesis and therapy. Curr Opin Genet Dev, 48, iv–vi.

Alajez

N.M.

, Shi

, Wong

, Lenarduzzi

, Waldron

, Weinreb

, et al. (2012). Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget, 3, 1641–1652.

Bartel

D.P.

(2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281–297.

Burd

C.G.

, and Dreyfuss

(1994). Conserved structures and diversity of functions of RNA-binding proteins. Science, 265, 615–621.

Desterro

, Bak-Gordon

, and Carmo-Fonseca

(2020). Targeting mRNA processing as an anticancer strategy. Nat Rev Drug Discov, 19, 112–129.

Dong

, Dai

Z.H.

, Liu

F.C.

, Guo

X.G.

, Ge

C.M.

, Ding

, et al. (2019). The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production. EBioMedicine, 45, 155–167.

Falcone

, and Mazzoni

(2018). RNA stability and metabolism in regulated cell death, aging and diseases. FEMS Yeast Res 18. DOI: 10.1093/femsyr/foy050.

Gerstberger

, Hafner

, and Tuschl

(2014). A census of human RNA-binding proteins. Nat Rev Genet, 15, 829–845.

Glisovic

, Bachorik

J.L.

, Yong

, and Dreyfuss

(2008). RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett, 582, 1977–1986.

10.

Hautbergue

G.M.

(2017). RNA nuclear export: from neurological disorders to cancer. Adv Exp Med Biol, 1007, 89–109.

11.

Kamps

, Brandao

R.D.

, Bosch

B.J.

, Paulussen

A.D.

, Xanthoulea

, Blok

M.J.

, et al. (2017). Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci 18, 308.

12.

Koh

C.M.

, Sabo

, and Guccione

(2016). Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays, 38, 266–275.

13.

Kudinov

A.E.

, Karanicolas

, Golemis

E.A.

, and Boumber

(2017). Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets. Clin Cancer Res, 23, 2143–2153.

14.

Lee

Y.S.

, and Dutta

(2009). MicroRNAs in cancer. Annu Rev Pathol, 4, 199–227.

15.

, Gao

L.N.

, Song

P.P.

, and You

C.G.

(2020a). Development and validation of a RNA binding protein-associated prognostic model for lung adenocarcinoma. Aging (Albany NY), 12, 3558–3573.

16.

, Li

, Gao

, and You

(2020b). Integrated analysis of the roles and prognostic value of RNA binding proteins in lung adenocarcinoma. PeerJ 8, e8509.

17.

, Li

, Gao

L.N.

, and You

C.G.

(2020c). Integrated analysis of the functions and prognostic values of RNA binding proteins in lung squamous cell carcinoma. Front Genet 11, 185.

18.

Majumder

, House

, Palanisamy

, Qie

, Day

T.A.

, Neskey

, et al. (2016). RNA-binding protein FXR1 regulates p21 and TERC RNA to bypass p53-mediated cellular senescence in OSCC. PLoS Genet 12, e1006306.

19.

Pereira

, Billaud

, and Almeida

(2017). RNA-binding proteins in cancer: old players and new actors. Trends Cancer, 3, 506–528.

20.

Perron

, Jandaghi

, Solanki

, Safisamghabadi

, Storoz

, Karimzadeh

, et al. (2018). A general framework for interrogation of mRNA stability programs identifies RNA-binding proteins that govern cancer transcriptomes. Cell Rep, 23, 1639–1650.

21.

Rupaimoole

, and Slack

F.J.

(2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov, 16, 203–222.

22.

Saramago

, da Costa

P.J.

, Viegas

S.C.

, and Arraiano

C.M.

(2019). The implication of mRNA Degradation Disorders on Human DISease: focus on DIS3 and DIS3-like enzymes. Adv Exp Med Biol, 1157, 85–98.

23.

Scott

S.E.

, Grunfeld

E.A.

, and McGurk

(2005). The idiosyncratic relationship between diagnostic delay and stage of oral squamous cell carcinoma. Oral Oncol, 41, 396–403.

24.

Talwar

, Jin

, Carroll

, Liu

, Gillespie

M.B.

, and Palanisamy

(2011). Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress. J Biol Chem, 286, 32333–32343.

25.

Tomczak

, Czerwinska

, and Wiznerowicz

(2015). The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn), 19(1A), A68–A77.

26.

Wang

, Qi

, and Hou

(2019). Systematically dissecting the function of RNA-binding proteins during glioma progression. Front Genet 10, 1394.

27.

C.S.

, Chang

K.P.

, Chen

L.C.

, Chen

C.C.

, Liang

, Hseuh

, et al. (2012). Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma. Oral Oncol, 48, 516–522.

28.

Yohe

, and Thyagarajan

(2017). Review of clinical next-generation sequencing. Arch Pathol Lab Med, 141, 1544–1557.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.04 MB

Comprehensive Analysis of the Roles and Prognostic Value of RNA-Binding Proteins in Head and Neck Squamous Cell Carcinoma

Abstract

Get full access to this article

References

Supplementary Material